| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.071 | 0.02 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.02 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.11 | 0.03 |